Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.

MDMA and MDMA-Assisted Therapy

Abstract

MDMA (i.e., 3,4-methylenedixoymethamphetamine), commonly known as "Ecstasy" or "Molly," has been used since the 1970s both in recreational and therapeutic settings. The Food and Drug Administration (FDA) designated MDMA-Assisted Therapy (MDMA-AT) as a Breakthrough Therapy for posttraumatic stress disorder (PTSD) in 2017, and the FDA is requiring an additional phase 3 trial after rejecting the initial New Drug Application in 2024. Unlike other psychedelics, MDMA uniquely induces prosocial subjective effects of heightened trust and self-compassion while maintaining ego functioning as well as cognitive and perceptual lucidity. While recreational use in nonmedical settings may still cause harm, especially due to adulterants or when used without proper precautions, conclusions that can be drawn from studies of recreational use are limited by many confounds. This especially limits the extent to which evidence related to recreational use can be extrapolated to therapeutic use. A considerable body of preliminary evidence suggests that MDMA-AT delivered in a controlled clinical setting is a safe and efficacious treatment for PTSD. After a course of MDMA-AT involving three MDMA administrations supported by psychotherapy, 67%-71% of individuals with PTSD no longer meet diagnostic criteria after MDMA-AT versus 32%-48% with placebo-assisted therapy, and effects endure at long-term follow-up. This review primarily aims to distinguish evidence of recreational use in nonclinical settings versus MDMA-AT using pharmaceutical-grade MDMA in controlled clinical settings. This review further describes the putative neurobiological mechanisms of MDMA underlying its therapeutic effects, the clinical evidence of MDMA-AT, considerations at the level of public health and policy, and future research directions.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.20230681

Cites

170 of 170 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

4 retracted

Show all 169 references

Research works printed but not linked: 18

  1. Greer G, 1985, Advances, 2, 57
  2. Young FL, 1986, In the Matter of MDMA Scheduling, Docket No 84-48, Opinion and Recommended Ruling, Findings of Fact, Conclusions of Law and Decision of Administrative Law Judge on Issues Two through Seven
  3. 10.1038/sj.npp.1395197 · DOI · Paper page
  4. Connolly E, 1999, Crit Care Resusc, 1, 368
  5. Battaglia G, 1987, J Pharmacol Exp Ther, 242, 911
  6. Vollenweider F, 2000, Effects of MDMA on 5-HT uptake sites using PET and [11C]-McN5652 in humans
  7. Stolaroff M, 2004, The Secret Chief Revealed: Conversations with Leo Zeff
  8. Multidisciplinary Association for Psychedelic Studies, 2021, MDMA Investigator’s Brochure (MDMA)
  9. Baggott MJ, 2016, Adv Pharmacol Sci, 2016, 2175896
  10. Mas M, 1999, J Pharmacol Exp Ther, 290, 136
  11. Baggott M, Jerome L, Stuart R: 3,4-methylenedioxymethamphetamine (MDMA): a review of the english-language scientific and medical literature 2001
  12. Parrott AC, 2000, Drug Alcohol Depend, 60, 105
  13. Potash MN, 2009, Psychiatry (Edgmont), 6, 40
  14. Volpi-Abadie J, 2013, Ochsner J, 13, 533
  15. Malberg JE, 1996, J Pharmacol Exp Ther, 278, 258
  16. Adamson S, 2012, Through the Gateway of the Heart: Accounts and Experiences with MDMA and Other Empathogenic Substances
  17. VA/DoD Clinical Practice Guidelines, 2023, Management of Posttraumatic Stress Disorder and Acute Stress Disorder
  18. Itzhaky L, 2014, J depress anxiety, 3, 1

Cited by

See all 62

Metadata

Authors
Wolfgang, A. S., Fonzo, G. A., Gray, J. C., Krystal, J. H., Grzenda, A., Widge, A. S., Kraguljac, N. V., McDonald, W. M., Rodriguez, C. I., & Nemeroff, C. B.
Affiliations
  • University of Minnesota (US)
  • Directorate of Behavioral Health, Walter Reed National Military Medical Center, Bethesda, MD (Wolfgang); Departments of Psychiatry (Wolfgang) and Medical and Clinical Psychology (Gray), Uniformed Services University, Bethesda, MD; Departments of Psychiatry (Wolfgang, Krystal), Neuroscience (Krystal), and Psychology (Krystal), Yale University School of Medicine, New Haven, CT; Center for Psychedelic Research and Therapy, Department of Psychiatry and Behavioral Sciences, The University of Texas at Austin...
Venue
American Journal of Psychiatry
Published
2025-01-01
Volume
182
Issue
1
Pages
79-103
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W4405977949
Cited by
62
References
169
Citations by year
2026: 34 · 2025: 27
FWCI
13.43
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
  • Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Keywords
MDMA, MDMA-assisted psychotherapy, ecstasy, post-traumatic stress disorder, psychedelic therapy, recreational drug use, drug adulteration, prosocial effects, neurobiological mechanisms, treatment efficacy, public health policy
MeSH terms
Hallucinogens, Humans, Psychotherapy, Stress Disorders, Post-Traumatic, N-Methyl-3,4-methylenedioxyamphetamine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MDMA and MDMA-Assisted Therapy. https://app.cochat.ai/papers/10.1176/appi.ajp.20230681
The paper
Wolfgang, A. S., Fonzo, G. A., Gray, J. C., Krystal, J. H., Grzenda, A., Widge, A. S., Kraguljac, N. V., McDonald, W. M., Rodriguez, C. I., & Nemeroff, C. B. (2025). MDMA and MDMA-Assisted Therapy. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.20230681

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.